Association Between the TP53 Codon 72 Polymorphism and Risk of Oral Squamous Cell Carcinoma in Asians: a Meta-analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2014 Jun 28

PMID 24969046

Citations 22

Authors

Xian-Tao Zeng

Wei Luo

Pei-Liang Geng

Yi Guo

Yu-Ming Niu

Wei-Dong Leng

Affiliations

Soon will be listed here.

Abstract

Background: Several epidemiological studies have previously investigated the association between the TP53 codon 72 polymorphism and oral squamous cell carcinoma (OSCC) susceptibility; however, current results are inconsistent. We therefore performed this meta-analysis to thoroughly investigate any association among Asian patients.

Methods: A comprehensive search of PubMed and Embase databases was performed up to December 2013. We only considered studies consisting of patients diagnosed with OSCC by pathological methods. Statistical analyses were performed using Review Manager (RevMan) 5.2 software and odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association.

Results: A total of 11 case-control studies involving 2,298 OSCC patients and 2,111 controls were included. We found no association between the TP53 codon 72 polymorphism and OSCC susceptibility [(OR = 0.77, 95% CI = 0.48-1.22) for Arg vs. Pro; (OR = 0.67, 95% CI = 0.31-1.43) ArgArg vs. ProPro; (OR = 1.14, 95% CI = 0.97-1.35) ArgPro vs. ProPro; (OR = 0.85, 95% CI = 0.53-1.34) (ArgPro + ArgArg) vs. ProPro; or (OR = 0.34, 95% CI = 0.34-1.23) for ArgArg vs. (ProPro + ArgPro)]. However, subgroup analysis demonstrated an association between the TP53 codon 72 polymorphism and human papillomavirus (HPV)-related OSCC patients. Although statistical heterogeneity was detected, there was no evidence of publication bias.

Conclusions: Current results suggest that the TP53 codon 72 polymorphism is not associated with OSCC in Asians without the presence of HPV infection. Further research is necessary to determine if such a relationship exists in HPV-related OSCC patients.

Citing Articles

Genomic and Immune Approach in Platinum Refractory HPV-Negative Head and Neck Squamous Cell Carcinoma Patients Treated with Immunotherapy: A Novel Combined Profile.

Mezi S, Pomati G, Zizzari I, Di Filippo A, Cerbelli B, Cirillo A Biomedicines. 2022; 10(11).

PMID: 36359251 PMC: 9687656. DOI: 10.3390/biomedicines10112732.

Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews.

Gonzalez-Moles M, Warnakulasuriya S, Lopez-Ansio M, Ramos-Garcia P Cancers (Basel). 2022; 14(15).

PMID: 35954497 PMC: 9367256. DOI: 10.3390/cancers14153834.

Frequency of somatic mutations in promoter, and genes in patients with hepatocellular carcinoma from Southern Italy.

Lombardo D, Saitta C, Giosa D, Casuscelli di Tocco F, Musolino C, Caminiti G Oncol Lett. 2020; 19(3):2368-2374.

PMID: 32194736 PMC: 7039085. DOI: 10.3892/ol.2020.11332.

Assad Samani L, Javadirad S, Parsafar S, Tabatabaeian H, Ghaedi K, Azadeh M Indian J Clin Biochem. 2019; 34(4):485-489.

PMID: 31686737 PMC: 6801240. DOI: 10.1007/s12291-018-0774-6.

Variants in FAT1 and COL9A1 genes in male population with or without substance use to assess the risk factors for oral malignancy.

Chung C, Hung C, Lee C, Lee C, Lee K, Chen M PLoS One. 2019; 14(1):e0210901.

PMID: 30657779 PMC: 6338366. DOI: 10.1371/journal.pone.0210901.

References

Kreimer A, Clifford G, Boyle P, Franceschi S . Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14(2):467-75. DOI: 10.1158/1055-9965.EPI-04-0551. View

Warnakulasuriya S . Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2008; 45(4-5):309-16. DOI: 10.1016/j.oraloncology.2008.06.002. View

Ghani W, Doss J, Jamaluddin M, Kamaruzaman D, Zain R . Oral cancer awareness and its determinants among a selected Malaysian population. Asian Pac J Cancer Prev. 2013; 14(3):1957-63. DOI: 10.7314/apjcp.2013.14.3.1957. View

Jiang N, Pan J, Wang L, Duan Y . No significant association between p53 codon 72 Arg/Pro polymorphism and risk of oral cancer. Tumour Biol. 2012; 34(1):587-96. DOI: 10.1007/s13277-012-0587-9. View

Niu Y, Shen M, Li H, Ni X, Zhou J, Zeng X . No association between MTHFR A1298C gene polymorphism and head and neck cancer risk: a meta-analysis based on 9,952 subjects. Asian Pac J Cancer Prev. 2012; 13(8):3943-7. DOI: 10.7314/apjcp.2012.13.8.3943. View

Lin Y, Huang H, Wang L, Tsai C, Lung O, Dai C . Polymorphisms of COX-2 -765G>C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol. 2008; 44(8):798-804. DOI: 10.1016/j.oraloncology.2007.10.006. View

Huedo-Medina T, Sanchez-Meca J, Marin-Martinez F, Botella J . Assessing heterogeneity in meta-analysis: Q statistic or I2 index?. Psychol Methods. 2006; 11(2):193-206. DOI: 10.1037/1082-989X.11.2.193. View

Sousa H, Santos A, Pinto D, Medeiros R . Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int J Mol Med. 2007; 20(5):731-41. View

Kuroda Y, Nakao H, Ikemura K, Katoh T . Association between the TP53 codon72 polymorphism and oral cancer risk and prognosis. Oral Oncol. 2007; 43(10):1043-8. DOI: 10.1016/j.oraloncology.2006.12.001. View

10.

Saleem S, Azhar A, Hameed A, Khan M, Abbasi Z, Qureshi N . P53 (Pro72Arg) polymorphism associated with the risk of oral squamous cell carcinoma in gutka, niswar and manpuri addicted patients of Pakistan. Oral Oncol. 2013; 49(8):818-23. DOI: 10.1016/j.oraloncology.2013.04.004. View

11.

Hollstein M, Sidransky D, Vogelstein B, Harris C . p53 mutations in human cancers. Science. 1991; 253(5015):49-53. DOI: 10.1126/science.1905840. View

12.

Brinkman B, Wong D . Disease mechanism and biomarkers of oral squamous cell carcinoma. Curr Opin Oncol. 2006; 18(3):228-33. DOI: 10.1097/01.cco.0000219250.15041.f8. View

13.

Zhuo X, Li Q, Zhou Y, Cai L, Xiang Z, Yuan W . Study on TP53 codon 72 polymorphisms with oral carcinoma susceptibility. Arch Med Res. 2010; 40(7):625-34. DOI: 10.1016/j.arcmed.2009.09.004. View

14.

Zhou Y, Li N, Zhuang W, Liu G, Wu T, Yao X . P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer. 2007; 121(7):1481-6. DOI: 10.1002/ijc.22833. View

15.

Goot Heah K, Abu Hassan M, Huat S . p53 Expression as a marker of microinvasion in oral squamous cell carcinoma. Asian Pac J Cancer Prev. 2011; 12(4):1017-22. View

16.

Tandle A, Sanghvi V, Saranath D . Determination of p53 genotypes in oral cancer patients from India. Br J Cancer. 2001; 84(6):739-42. PMC: 2363816. DOI: 10.1054/bjoc.2000.1674. View

17.

Xu T, Xu Z, Zou Q, Yu B, Huang X . P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev. 2012; 13(5):2349-54. DOI: 10.7314/apjcp.2012.13.5.2349. View

18.

Ara S, Lee P, Hansen M, Saya H . Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 1990; 18(16):4961. PMC: 332028. DOI: 10.1093/nar/18.16.4961. View

19.

Nagpal J, Patnaik S, Das B . Prevalence of high-risk human papilloma virus types and its association with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of Eastern India. Int J Cancer. 2002; 97(5):649-53. DOI: 10.1002/ijc.10112. View

20.

Tu H, Chen H, Kao S, Lin S, Liu C, Chang K . MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother Oncol. 2008; 87(2):243-52. DOI: 10.1016/j.radonc.2008.03.018. View